The effects of altered apolipoprotein A-I structure on plasma HDL concentration

Trends in Cardiovascular Medicine

Volumn 12, Issue 3, 2002, Pages 121-128

  Sorci Thomas, Mary G ^a   Thomas, Michael J ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN; MUTANT PROTEIN; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; AMYLOIDOSIS; ENZYME ACTIVATION; HUMAN; LIPOPROTEIN BLOOD LEVEL; MUTATION; NONHUMAN; NUCLEOTIDE REPEAT; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN TERTIARY STRUCTURE; PROTEIN VARIANT; REVIEW; STEADY STATE;

AMINO ACID SEQUENCE; AMINO ACIDS; AMYLOIDOSIS; APOLIPOPROTEIN A-I; ENZYME ACTIVATION; HUMANS; LIPOPROTEINS, HDL; MUTATION; PHOSPHATIDYLCHOLINE-STEROL O-ACYLTRANSFERASE; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 0036234218     PISSN: 10501738     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1050-1738(01)00163-3     Document Type: Review

References (66)

1. Extensive intimal apolipoprotein A1-derived amyloid deposits in a patient with an apolipoprotein A1 mutation
2. Characterization of two new human apolipoprotein A-I variants: Apolipoprotein A-I Tsushima (Trp-108→Arg) and A-I Hita (Ala-95→Arg;Asp)
3. Hereditary amyloid cardiomyopathy caused by a variant apolipoprotein A1
4. A novel apolipoprotein A-1 variant, Arg173Pro, associated with cardiac and cutaneous amyloidosis
5. High density lipoproteins, reverse transport of cholesterol, and coronary artery disease. Insights from mutations
6. High density lipoprotein particle size restriction in apolipoprotein A-I Milano transgenic mice
7. In vivo metabolism of proapolipoprotein A-I in Tangier disease patients
8. A new apolipoprotein A-I variant, Trp50Arg, causes hereditary amyloidosis
9. Hereditary hepatic and systemic amyloidosis caused by a new deletion/insertion mutation in the apolipoprotein AI gene
10. Apolipoprotein genetic variation and human disease
11. Structural models of human apolipoprotein A-I: A critical analysis and review
12. A key point mutation in (V156E) affects the structure and functions of human apolipoprotein A-I
13. Paris is defective in activation of lecithin:cholesterol acyltransferase but not in initial lipid binding, formation of reconstituted lipoproteins, or promotion of cholesterol efflux
14. Oslo and apoA-I(P165R), that are associated with hypoalphalipoproteinemia in heterozygous carriers
15. A mutation in the human apolipoprotein A-I gene. Dominant effect on the level and characteristics of plasma high density lipoproteins
16. 66 paired helix of apolipoprotein A-I in lecithin:cholesterol acyltransferase activation
17. Apolipoprotein A-I: Structure-function relationships
18. Importance of central α-helices of human apolipoprotein A-I in the maturation of high density lipoproteins
19. A frameshift mutation in the human apolipoprotein A-I gene causes high density lipoprotein deficiency, partial lecithin:cholesterol-acyltransferase deficiency, and corneal opacities
20. A novel mutant, apoA-I nichinan (Glu235→0) is associated with low HDL cholesterol levels and decreased cholesterol efflux from cells
21. Cholesterol efflux regulatory protein, Tangier disease and familial high-density lipoprotein deficiency
22. A novel homozygous missense mutation in the apoA-I gene with apoA-I deficiency
23. HDL deficiency in genetically engineered mice requires elevated LDL to accelerate atherogenesis
24. The antiatherogenic role of high-density lipoprotein cholesterol
25. Apolipoprotein AI Baltimore (Arg10→Leu), a new apoAI variant
26. Deletion of amino acids Glu146 to Arg 160 in human apolipoprotein A-I (apoA-ISeattle) alters lecithin:cholesterol acyltransferase activity and recruitment of cell phospholipid
27. Plasma lipoproteins: Apolipoprotein structure and function
28. ApoA-I Mallorca (deletion of amino acids 165-175) impairs LCAT activation and induces dominant familial hypoalphalipoproteinemia
29. Apolipoprotein A-I deficiency due to a codon 84 nonsense mutation of the apolipoprotein A-I gene
30. Proteolytic degradation and impaired secretion of an apolipoprotein A-I mutant associated with dominantly inherited hypoalphalipoproteinemia
31. 1-HDL and influences efflux of cholesterol into plasma
32. FIN:Dominantly inherited hypoalphalipoproteinemia due to a single base substitution in the apolipoprotein A-I gene
33. FIN (Leu159→ Arg) mutation affects lecithin-cholesterol acyltransferase activation and subclass distribution of HDL but not cholesterol efflux from fibroblasts
34. 159→Pro) HDL cholesterol deficiency in a kindred associated with premature coronary artery disease
35. A cysteine-containing truncated apoA-I variant associated with HDL deficiency
36. Identification of two apolipoprotein variants, A-I Karatsu (Tyr 100→His) and A-I Kurume (His 162→Gin)
37. Molecular basis of exchangeable apolipoprotein function
38. Apoliporotein A-I Q[-2]X causing isolated apolipoprotein A-I deficiency in a family with analphalipoproteinemia
39. Variant apolipoprotein AI as a major constituent of a human hereditary amyloid
40. Effects of apolipoprotein A-I deficiency on lecithin:cholesterol acyltransferase activation in mouse plasma
41. Apolipoprotein A-I transgene corrects apolipoprotein deficiency-induced atherosclerosis in mice
42. Hereditary nephropathic systemic amyloidosis caused by a novel variant apolipoprotein A-I
43. Iowa, associated with hypoalphalipoproteinemia and hereditary systemic amyloidosis
44. Abnormal lecithin:cholesterol acyltransferase activation by a human apolipoprotein A-I variant in which a single lysine residue is deleted
45. Zaragoza (L144R)
46. A nonsense mutation in the apolipoprotein A-I gene is associated with high density lipoprotein deficiency and periorbital xanthelasmas
47. Three arginine residues in apolipoprotein A-I are critical for activation of lecithin:cholesterol acyltransferase
48. Targeted disruption of the mouse lecithin:cholesterol acyltransferase (LCAT) gene
49. Structure and function of apolipoprotein A-I and high denisty lipoprotein
50. Recombinant apolipoproteins for the treatment of vascular diseases
51. Apolipoprotein A-I domains involved in lecithin:cholesterol acyltransferase activation: Structure:function relationships
52. Alterations in apolipoprotein A-I 22-mer repeat order results in a decrease in lecithin:cholesterol acyltransferase reactivity
53. The hydrophobic face orientation of apolipoprotein A-I amphipathic helix domain 143-164 regulates lecithin:cholesterol acyltransferase activation
54. Single repeat deletion in apoA-I blocks cholesterol esterification and results in rapid catabolism of Δ6 and wild-type apoA-I in transgenic mice
55. Apolipoprotein A-I mutation Arg-60 causes autosomal dominant amyloidosis
56. Identification of a sequence of apolipoprotein A-I associated with the activation of lecithin:cholesterol acyltransferase
57. Isolation and characterization of human apolipoprotein A-I Fukuoka (110 Glu→ Lys). A novel apolipoprotein variant
58. Characterization of a new human apolipoprotein A-I Yame by direct sequencing of polymerase chain reaction-amplified DNA
59. Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice
60. 107→0) associated with reduced HDL cholesterol and LpA-I:A-II deficiency
61. The role of high-density lipoprotein receptor SR-B1 in cholesterol metabolism
62. Inherited predisposition to generalized amyloidosis. Clinical and pathological study of a family with neuropathy, nephropathy, and peptic ulcer
63. Apolipoprotein A-I variants: Naturally occurring substitutions of proline residues affect plasma concentration of apolipoprotein A-I
64. Structural analysis of human apolipoprotein A-I variants. Amino acid substitutions are nonrandomly distributed throughout the apolipoprotein A-I primary structure
65. A-I Milano apoprotein isolation and characterization of a cysteine-containing variant of the A-I apoprotein from human high density lipoproteins
66. Frequent occurrence of hypoalphalipoproteinemia due to mutant apolipoprotein A-I gene in the population: A population-based survey